Anti-TNF biologic agents Dr Lluís Puig
|
|
- Toby Terry
- 6 years ago
- Views:
Transcription
1 Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013
2 Anti-TNF therapy in the pathophysiology model Adapted from: Nestle FO, Kaplan DH, Barker J. N Engl J Med. 2009;361(5):
3 Etanercept
4 Etanercept Structure! Human fusion protein composed of TNF receptor type II (TNF-R p75) and human IgG1 Fc fragment Target! TNF-α and TNF-β (lymphotoxin-α) Presumed mechanism of action! Attenuates inflammatory action of TNF by interfering with binding to cell-surface receptors Human p75 TNF receptor Complement binding region F c Etanercept - European Summary of Product Characteristics. Date: November 2009.
5 Etanercept Mechanism of action Macrophage or activated T cell Transmembranebound TNF Soluble TNF TNF receptor Target cell Etanercept - European Summary of Product Characteristics. Date: November 2009.
6 Etanercept Pivotal phase 3 studies in psoriasis Lead author Papp Leonardi Tyring N (patients) Trial duration (blinded/open label) 12 weeks placebocontrolled followed by 12 weeks blinded 12 weeks placebocontrolled followed by 12 weeks blinded 12 weeks placebocontrolled followed by 132 weeks open label Patient population Active plaque psoriasis PASI 10, BSA 10% Active plaque psoriasis PASI 10, BSA 10% Active plaque psoriasis PASI 10, BSA 10% Primary endpoint PASI 75 at week 12 PASI 75 at week 12 PASI 75 at week 12 Dosage and design 25 mg BIW or 50 mg BIW vs placebo until week 12 From week 12 all groups 25 mg BIW 25 mg QW or 25 mg BIW or 50 mg BIW vs placebo Placebo crossover to 25 mg BIW at week mg BIW vs placebo Placebo crossover to 50 mg BIW at week 12 Papp KA, et al. Br J Dermatol. 2005;152(6): Leonardi CL, et al. N Engl J Med. 2003;349(21): Tyring S, et al. Arch Dermatol. 2007;143(6):
7 Etanercept PASI 75 responses at week 12 in the pivotal studies Patients (%) * 49* 34* 49* weeks 12 weeks US study 1 Global study 2 Placebo Etanercept 25 mg BIW Etanercept 50 mg BIW *p< vs placebo 1. Leonardi CL, et al. N Engl J Med. 2003;349: ; 2. Papp KA, et al. Br J Dermatol. 2005;152:
8 Etanercept PASI 75 responses through week 24 in a pivotal clinical study 70 PASI 75 response through week 24 All patients switched to etanercept 25 mg BIW at week 12 Etanercept 25 mg B/W % 50% Patients (%) % 42% 26% * 3% Weeks *p= vs. placebo; p< vs. placebo; p=0.004 vs. etanercept 25 mg BIW; Analysis is ITT Placebo Etanercept 25 mg B/W Etanercept 50 mg B/W Papp KA, et al. Br J Dermatol. 2005; 152:
9 Etanercept PGA responses at Weeks 12 and Physician s global assessment of psoriasis: clear or almost clear response 80 Patients (%) * weeks 24 weeks *p<0.001 vs QW Week 0-24 Sterry W, et al. BMJ. 2010;340:c147. Etanercept 50 mg BIW Week 0-12 QW Week Etanercept 50 mg QW Week 0-24
10 Etanercept PASI 75 response through 96 weeks Placebo Etanercept 50 mg BIW 100 Weeks 0-12: placebo-controlled phase Weeks 12-96: open-label phase (missing data was imputed using LOCF analysis)* 80 Patients (%) * *p<0.001 vs placebo Weeks *Duration of open-label treatment was extended to 132 weeks. Tyring S, et al. Arch Dermatol. 2007;143:
11 Etanercept DLQI response through 54 weeks * Meaningful improvement in DLQI Total Score * * * * Patients (%) * Patients in continuous or paused etanercept group showing 5 point improvement Daudén E, et al. J Eur Acad Dermatol Venereol. 2009;23(12): *p<0.05 difference between the continuous and paused groups at 6 of 11 observed post-baseline visists Week Continuous therapy Paused therapy
12 Etanercept Safety and tolerability! Common or very common* adverse events (from clinical studies and post-marketing surveillance) Infections (including upper respiratory tract infections, bronchitis, cystitis, skin infections), allergic reactions, autoantibody formation, pruritus, injection site reactions (including bleeding, bruising, erythema, itching, pain, swelling), fever Approximately 13.6% of patients treated with etanercept developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment! Special warnings and precautions for use relate to: Infections, tuberculosis, hepatitis B reactivation, worsening of hepatitis C, concurrent treatment with anakinra, concurrent treatment with abatacept, allergic reactions, immunosuppression, malignancies and lymphoproliferative disorders, vaccinations, autoantibody formation, haematologic reactions, CNS disorders, congestive heart failure, alcoholic hepatitis, Wegener's granulomatosis * Very common ( 1/10) Common ( 1/100 to <1/10) Etanercept - European Summary of Product Characteristics. Date: November 2009.
13 Etanercept Formation of antibodies! The formation of antibodies to etanercept has been observed in some patients, but these have been non-neutralising and are generally transient 1! There appears to be no correlation between antibody development and clinical response or adverse effects 1 Non-neutralising antibodies to etanercept have been observed in 18% of patients with no apparent effect on efficacy or safety 2 1. Etanercept - European Summary of Product Characteristics. Date: November Tyring S, Gordon KB, Poulin Y, et al. Arch Dermatol 2007; 143(6):
14 Etanercept in children and adolescents Efficacy at Week 12 PASI 75 (Primary endpoint) Physician s Global Assessment clear or almost clear Patients (%) * * n=105 n=106 n=105 n=106 Placebo Etanercept 0.8 mg/kg *p<0.001 vs placebo Paller AS, et al. N Engl J Med. 2008;358(3): Note: Data from patients who entered the escape group were imputed as nonresponses.
15 Etanercept in children and adolescents Efficacy through Week Double-blind PASI 75 response Open-label Patients (%) Weeks Etanercept weeks 1 36 Placebo Weeks 1 12, etanercept weeks Paller AS, et al. N Engl J Med. 2008;358(3): Note: Up to week 12, data from patients who entered the escape group were not imputed as nonresponses.
16 Etanercept in children and adolescents Safety and tolerability! Double blind phase: no serious adverse events (including serious infections, TB, and malignancy) were reported! Open label phase: four serious adverse events (including three infections) occurred in three patients receiving etanercept; all resolved without sequelae Paller AS, et al. N Engl J Med. 2008;358(3):
17 Infliximab
18 Infliximab Structure! Chimeric monoclonal antibody with murine (mouse) variable region and human IgG1 region Anti-TNF-α Murine variable region Target! TNF-α Presumed mechanism of action! Attenuates inflammatory action of TNF-α by interfering with binding to cell-surface receptors! Apoptosis of TNF-α-positive macrophages and T cells Human IgG1 region Infliximab - European Summary of Product Characteristics. Date: March 2010.
19 Infliximab Mechanism of action Macrophage or activated T cell Receptor-bound TNF-α Soluble TNF-α Transmembranebound TNF-α TNF receptor Target cell Infliximab - European Summary of Product Characteristics. Date: March 2010.
20 Infliximab Pivotal phase 3 studies in psoriasis Lead author Reich Menter N (patients) Trial duration (blinded/open label) Patient population 24 weeks placebo-controlled followed by 22 weeks open label Active plaque psoriasis PASI 12, BSA 10% 50 weeks (including 16 weeks placebo controlled) Active plaque psoriasis PASI 12, BSA 10% Primary endpoint PASI 75 at week 10 PASI 75 at week 10 Dosage and design 5 mg/kg at weeks 0, 2, 6 and every 8 weeks vs placebo Placebo crossover to 5 mg/kg at week 24 5 mg/kg or 3 mg/kg at weeks 0, 2, 6 vs placebo Placebo crossover to 5 mg/kg at week 16, 18, 22 and every 8 weeks thereafter Treatment groups re-randomised at week 14 to maintenance or intermittent therapy Reich K, et al. Lancet. 2005;366: Menter A, al. J Am Acad Dermatol. 2007;56(1):e1-e15.
21 Infliximab PASI 75 responses at week * 70.3 * 75.5 * Patients (%) *p< vs placebo EXPRESS 1 EXPRESS II 2 Placebo Infliximab 3 mg/kg Infliximab 5 mg/kg 1. Reich K, et al. Lancet. 2005;366: Menter A, al. J Am Acad Dermatol. 2007;56(1):e1-e15.
22 Infliximab PASI 75 responses through 50 weeks 100 EXPRESS 1 (week 50) Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks 100 EXPRESS II 2 (week 50) Infliximab 5 mg/kg every 8 weeks (randomised at week 14) Patients (%) mg/kg 61% mg/kg 54.5% Weeks Weeks 1. Reich K, et al. Lancet. 2005;366: Menter A, al. J Am Acad Dermatol. 2007;56(1):e1-e15.
23 Infliximab vs methotrexate PASI 75 responses at Weeks 16 and 26 Restore * 77* *p<0.001 vs placebo Patients (%) Week 16 Week 26 *p<0.001 vs placebo Methotrexate 5 mg/week Infliximab 5 mg/kg Data available from: Accessed: 29 Apr 2010.
24 Infliximab Quality of life (DLQI) at 10 weeks and 24 weeks Mean change from baseline DLQI score Week 10 Week Clinically meaningful improvement * -10.0* * p<0.001 vs placebo Mean baseline DLQI values: placebo 11.8; infliximab Placebo Infliximab 5 mg/kg 1. Reich K, et al. Br J Dermatol. 2006;154(6): Khilji FA, et al. Br J Dermatol. 2002;147(Suppl 2):50.
25 Infliximab Safety and tolerability! Common or very common* adverse events (from clinical studies and post-marketing surveillance) Viral infection, serum sickness-like reaction, headache, vertigo, dizziness flushing, lower respiratory tract infection, upper respiratory tract infection, sinusitis, dyspnoea, abdominal pain, diarrhoea, nausea, dyspepsia, transaminases increased, urticaria, rash, pruritus, hyperhidrosis, dry skin, infusion-related reaction, chest pain, fatigue, fever In clinical studies, approximately 20% of infliximab-treated patients compared with approximately 10% of placebo-treated patients experienced an infusion-related effect! Special warnings and precautions for use relate to: Infusion reactions and hypersensitivity, infections (including TB), hepatitis B reactivation, hepatobiliary events, concurrent administration of anakinra, concurrent administration of abatacept, vaccinations, autoimmune processes, neurological events, malignancies and lymphoproliferative disorders, heart failure, surgical procedures * Very common ( 1/10) Common ( 1/100 to <1/10) Infliximab - European Summary of Product Characteristics. Date: March 2010.
26 Infliximab Formation of antibodies! In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab 1 The development of antibodies is weakly correlated to reduced duration of response 2,3 Antibodies to infliximab have been associated with an increased frequency of infusion reactions 1! Antinuclear antibody formation is seen in ~50% infliximab-treated patients (~20% controls) 1 Lupus and lupus-like syndromes are uncommon 1 1. Infliximab, Summary of Product Characteristics (EMEA). 2. Reich K, et al. Lancet. 2005; 366: Gottlieb AB, Evans R, Li S, et al. J Am Acad Dermatol 2004; 51(4):
27 Adalimumab
28 Adalimumab Structure! Fully human monoclonal antibody Human anti-tnf-α Target! TNF-α Presumed mechanism of action! Attenuates inflammatory action of TNF-α by interfering with binding to cell-surface receptors! Apoptosis of TNF-α-positive macrophages and T cells Adalimumab - European Summary of Product Characteristics. Date: April 2010.
29 Adalimumab Mechanism of action Macrophage or activated T cell Receptor-bound TNF-α Soluble TNF-α Transmembranebound TNF-α TNF receptor Target cell Adalimumab - European Summary of Product Characteristics. Date: April 2010.
30 Adalimumab Pivotal phase 3 studies in psoriasis Study REVEAL CHAMPION N (patients) Trial duration (blinded/open label) 16 weeks blinded, 17 weeks open label, 19 weeks blinded 16 weeks double-blind, double-dummy Patient population PASI 12, BSA 10% PASI 10, BSA 10% Primary endpoint Dosage and design PASI 75 at week 16 Loss of PASI 50 from week 33 to week mg at week 0, then 40 mg EOW from week 1 vs placebo (2:1 randomisation) PASI 75 at week mg at week 0, then 40 mg EOW from week 1 vs methotrexate ( mg) vs placebo (2:2:1 randomisation) REVEAL: Menter A, et al. J Am Acad Dermatol. 2008;58(1): CHAMPION: Saurat JH, et al. Br J Dermatol. 2008;158(3):
31 Adalimumab PASI 75 responses in the REVEAL study * 71* Patients (%) * 3 54* Week 4 Week 8 Week 12 Week 16 Primary endpoint *p<0.001, adalimumab vs placebo Menter A, et al. J Am Acad Dermatol. 2008;58(1): Placebo (n=398) Adalimumab (n=814)
32 Adalimumab vs methotrexate PASI 75 responses through Week * p<0.001 vs placebo p<0.001 vs MTX p=0.001 vs placebo Champion 77* 80* Patients (%) * 36 23* Week 4 Week 8 Week 12 Week 16 Saurat JH, et al. Br J Dermatol. 2008;158: Placebo (n=53) MTX mg/wk (n=110) Adalimumab (n=108)
33 Adalimumab Quality of life (DLQI) at 16 weeks 0 Placebo (n=53) Methotrexate mg (n=108) Adalimumab 40 mg EOW (n=103) Mean change from baseline DLQI score Clinically meaningful improvement *, *p<0.001 vs placebo; p<0.001 vs methotrexate Mean baseline DLQI scores: placebo 11.7; methotrexate 9.8; adalimumab Revicki D, et al. Br J Dermatol. 2008;158(3): Khilji FA, et al. Br J Dermatol. 2002;147(Suppl 2):50.
34 Adalimumab Safety and tolerability! Very common* adverse events (from clinical studies) Respiratory tract infections, leucopenia, anaemia, lipids increased, headache, abdominal pain, nausea and vomiting, elevated liver enzymes, rash, musculoskeletal pain, injection site reactions! In the pivotal controlled trials, 15% of patients treated with adalimumab developed injection site reactions compared to 9% of patients receiving placebo or active control *Very common ( 1/10) Adalimumab - European Summary of Product Characteristics. Date: April 2010.
35 Adalimumab Safety and tolerability Common* adverse events (from clinical studies)! Systemic infections, intestinal infections, skin and soft tissue infections, ear infections, oral infections, reproductive tract infections, urinary tract infections, fungal infections, benign neoplasm, skin cancer excluding melanoma, thrombocytopaenia, leucocytosis, hypokalaemia, uric acid increased, blood sodium abnormal, hypocalcaemia, hyperglycaemia, hypophosphotaemia, blood potassium increased, mood alterations, anxiety, insomnia, paraesthesias, migraine, sciatica, visual impairment, conjunctivitis, vertigo, tachycardia, hypertension, flushing, haematoma, cough, asthma, dyspnoea, GI haemorrhage, dyspepsia, gastroesophageal reflux disease, sicca syndrome, pruritus, urticaria, bruising, dermatitis, onychoclasis, hyperhydrosis, muscle spasms, haematuria, renal impairment, chest pain, oedema, coagulation and bleeding disorders, autoantibody test positive, blood lactate dehydrogenase increased, impaired healing Special warnings and precautions for use relate to:! Infections, serious infections, tuberculosis, other opportunistic infections, neurological events, allergic reactions, immunosuppression, malignancies and lymphoproliferative disorders, haematologic reactions, vaccinations, congestive heart failure, autoimmune processes, concurrent administration of anakinra, concurrent administration of abatacept, surgery *Common ( 1/100 to <1/10) Adalimumab - European Summary of Product Characteristics. Date: April 2010.
36 Adalimumab Formation of antibodies Adalimumab treatment has resulted in the development of antibodies in 8% of plaque psoriasis patients studied 1! Although antibody formation to adalimumab results in an increased clearance and a reduction in efficacy, there is no apparent correlation between the presence of anti-adalimumab antibodies and adverse effects 1,2 May result in the formation of autoimmune antibodies 1! However, new onset lupus-like syndrome is rare (2/3441 patients in rheumatoid arthritis and psoriatic arthritis clinical studies) 1 1. Adalimumab - European Summary of Product Characteristics. Date: April Menter A, et al. J Am Acad Dermatol. 2008; 58:
THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationCimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients Rapid, sustained and clinically meaningful improvement in wideranging patient-reported
More informationDRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.
DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationHELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationPACKAGE INSERT. Each vial of the REVELLEX product contains 100 mg of infliximab. After reconstitution, each vial
PACKAGE INSERT SCHEDULING STATUS S4 PROPRIETARY NAME AND DOSAGE FORM REVELLEX 100 mg COMPOSITION Each vial of the REVELLEX product contains 100 mg of infliximab. After reconstitution, each vial of REVELLEX
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationBiologic Therapies for Psoriasis. A Systematic Review
Biologic Therapies for Psoriasis. A Systematic Review WOLF-HENNING BOEHNCKE, JÖRG PRINZ, and ALICE B. GOTTLIEB ABSTRACT. Alefacept, efalizumab, etanercept, and infliximab are currently approved for the
More informationPRIOR AUTHORIZATION REQUEST GUIDE
PRIOR AUTHORIZATION REQUEST GUIDE Drafting a Prior Authorization Request The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationAUSTRALIAN PI HUMIRA (ADALIMUMAB) SOLUTION FOR SUBCUTANEOUS INJECTION
AUSTRALIAN PI HUMIRA (ADALIMUMAB) SOLUTION FOR SUBCUTANEOUS INJECTION 1 NAME OF THE MEDICINE Adalimumab (rch) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Humira (adalimumab) is a recombinant human immunoglobulin
More informationOff-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy Elizabeth A. Brezinski 2, April W. Armstrong 1 * 1 Department of Dermatology, University of
More informationAnnouncing HUMIRA. Psoriasis Starter Package
Announcing HUMIRA (adalimumab) Psoriasis Starter Package HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationNew Cimzia data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients
Long-term Cimzia (certolizumab pegol) data demonstrated rapid sustained improvements in clinical outcomes and quality of life in moderate to severe rheumatoid arthritis (RA) patients New Cimzia data, with
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 15 November 2007 Product name: Humira Procedure number: EMEA/H/C/481/II/38 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Simponi 100 mg solution for injection in pre-filled pen. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml pre-filled pen
More informationRheumatoid Arthritis. Module III
Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Humira 20 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.2 ml single dose
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRODUCT MONOGRAPH REMICADE. Infliximab. Powder for Solution, Sterile, Lyophilized, 100 mg/vial. Biological Response Modifier
PRODUCT MONOGRAPH REMICADE Infliximab Powder for Solution, Sterile, Lyophilized, 100 mg/vial Biological Response Modifier REMICADE should be used by physicians who have sufficient knowledge of rheumatoid
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More informationThe implication of an immunologic
Evidence-Based Review of Biologic Therapy for Psoriasis: Infliximab, Etanercept, Adalimumab, Efalizumab, and Alefacept Jeffrey M. Weinberg, MD; Robin Buchholz, MD; Noah Scheinfeld, MD DERMATOLOGY ABSTRACT
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationAbatacept: first T cell co-stimulation modulator for severe active RA
Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method
More informationWARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
More informationFaculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2015. The content and views presented in this educational activity are those of the
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationUSTEKINUMAB and BRIAKINUMAB
USTEKINUMAB and BRIAKINUMAB Andrew Blauvelt, M.D. Professor, Dept. of Dermatology and Dept. of Molecular Microbiology & Immunology Oregon Health & Science University Chief, Dermatology Service Veteran
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationAnti-Tumor Necrosis Factor (Anti-TNF)
Anti-Tumor Necrosis Factor (Anti-TNF) 110465 Anti-TNF.indd 1 9/20/16 9:01 AM s About your medicine Anti-tumor necrosis factor (anti-tnf) is a type of medicine called biologic agent that targets substance
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr INFLECTRA (infliximab for Injection) INFLECTRA is a subsequent entry biologic (SEB) to REMICADE. An SEB is a biologic drug product that is authorized based on its likeness
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationHUMIRA (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection,
More informationCimzia shows duration of response up to week 26 in moderate to severe Crohn s patients who failed the intravenous infusion treatment infliximab.
C3073-0409 CIMZIA (certolizumab pegol) PROVIDES LONG-TERM REMISSION AND RESPONSE RATES IN INFLIXIMAB-REFRACTORY CROHN S PATIENTS Cimzia shows duration of response up to week 26 in moderate to severe Crohn
More informationTREMFYA. guselkumab AUSTRALIAN PRODUCT INFORMATION
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationHumira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 13 December 2007 Product name: Humira Procedure number: EMEA/H/C/481/II/43 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74
More informationREMICADE Infliximab Consumer Medicine Information
REMICADE Infliximab Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does not take the place
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized
More informationEfficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept
Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept Robert Bissonnette, MD, FRCPC, a Chantal Bolduc, MD, FRCPC, a Yves Poulin, MD,
More informationMedical Coverage Guidelines are subject to change as new information becomes available.
ENBREL (etanercept) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. HUMIRA adalimumab (rch) solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION HUMIRA 10 mg: each 0.2 ml single-use pre-filled syringe contains 10 mg of adalimumab.
More informationSCIENTIFIC DISCUSSION. London, 26 April 2007 Product name: Humira/Trudexa Procedure number: EMEA/H/C/ /II/33
SCIENTIFIC DISCUSSION London, 26 April 2007 Product name: Humira/Trudexa Procedure number: EMEA/H/C/481-482/II/33 1. Introduction Adalimumab is a recombinant human immunoglobulin (IgG 1 ) monoclonal antibody
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr INFLECTRA (infliximab for Injection) INFLECTRA is a subsequent entry biologic (SEB) to REMICADE. An SEB is a biologic drug product that is authorized based on its likeness
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION PR RENFLEXIS TM (pronounced) (Infliximab for Injection) Powder for Solution, Sterile, Lyophilized, 100
More informationSCIENTIFIC DISCUSSION. London, 27 April 2006 Product name: HUMIRA/TRUDEXA Procedure number: EMEA/H/C/ /II/26
SCIENTIFIC DISCUSSION London, 27 April 2006 Product name: HUMIRA/TRUDEXA Procedure number: EMEA/H/C/481-482/II/26 3.1. Introduction Adalimumab is a recombinant human immunoglobulin (IgG 1 ) monoclonal
More informationREMICADE POWDER FOR INJECTION
REMICADE POWDER FOR INJECTION infliximab NEW ZEALAND DATA SHEET 1. PRODUCT NAME REMICADE 100 mg POWDER FOR INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of the REMICADE product contains
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More informationWeeks 2 and 4, followed by 200 mg every other week may be considered.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA safely and effectively. See full prescribing information for CIMZIA. CIMZIA (certolizumab
More informationAUSTRALIAN PRODUCT INFORMATION ORENCIA (ABATACEPT)
AUSTRALIAN PRODUCT INFORMATION ORENCIA (ABATACEPT) 1 NAME OF THE MEDICINE ORENCIA (abatacept) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Abatacept is a fusion protein produced by recombinant DNA technology
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 HUMIRA 40 mg, solution for injection in pre-filled syringe B/2 x 0.8 ml pre-filled glass syringes with
More informationPRODUCT MONOGRAPH SIMPONI. (golimumab) Solution for Injection. 50 mg/0.5 ml 100 mg/1.0 ml. SIMPONI I.V. (golimumab)
PRODUCT MONOGRAPH SIMPONI (golimumab) Solution for Injection 50 mg/0.5 ml 100 mg/1.0 ml SIMPONI I.V. (golimumab) Solution for Infusion 50 mg/4.0 ml Tumour necrosis factor alpha (TNFα) inhibitor SIMPONI
More informationSTELARA. ustekinumab NEW ZEALAND DATA SHEET
ustekinumab NEW ZEALAND DATA SHEET 1. PRODUCT NAME 45 mg solution for injection in vial. 90 mg solution for injection in vial. 45 mg solution for injection in pre-filled syringe. 90 mg solution for injection
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ORENCIA 250 mg powder for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INFLECTRA safely and effectively. See full prescribing information for INFLECTRA. INFLECTRA (infliximab-dyyb)
More informationActemra concentrate for intravenous infusion
Consumer Medicine Information Actemra concentrate for intravenous infusion Tocilizumab 80 mg in 4 ml, 200 mg in 10 ml and 400 mg in 20 ml concentrate for solution for infusion What is in this leaflet This
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More information0.8 mg/kg weekly, with a maximum of 50 mg per week
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ERELZI TM safely and effectively. See full prescribing information for ERELZI. ERELZI (etanercept-szzs)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Humira 40 mg solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.8 ml single dose vial contains 40 mg
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationMast Cell Activation Syndrome
Mast Cell Activation Syndrome Clinical Questionnaire Description Today s Date: Patient Name: Please indicate yes or no for the following symptoms and traits: (If you are not familiar with a particular
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections
More informationMonitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD
Monitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD Biologics available for psoriasis 1) tumor necrosis factor alpha (TNF-α) inhibitors, 2) interleukin (IL)-12/23 inhibitors, and
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationORENCIA (oh-ren-see-ah) (abatacept)
17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive
More information